Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

ADC Therapeutics (ADCT) Total Non-Current Liabilities: 2019-2022

Historic Total Non-Current Liabilities for ADC Therapeutics (ADCT) over the last 3 years, with Dec 2022 value amounting to $341.5 million.

  • ADC Therapeutics' Total Non-Current Liabilities rose 30.49% to $442.9 million in Q3 2023 from the same period last year, while for Sep 2023 it was $442.9 million, marking a year-over-year increase of 30.49%. This contributed to the annual value of $341.5 million for FY2022, which is 9.65% down from last year.
  • ADC Therapeutics' Total Non-Current Liabilities amounted to $341.5 million in FY2022, which was down 9.65% from $377.9 million recorded in FY2021.
  • In the past 5 years, ADC Therapeutics' Total Non-Current Liabilities ranged from a high of $377.9 million in FY2021 and a low of $6.6 million during FY2019.
  • Moreover, its 2-year median value for Total Non-Current Liabilities was $359.7 million (2021), whereas its average is $359.7 million.
  • Data for ADC Therapeutics' Total Non-Current Liabilities shows a maximum YoY decreased of 9.65% (in 2022) over the last 5 years.
  • Yearly analysis of 3 years shows ADC Therapeutics' Total Non-Current Liabilities stood at $6.6 million in 2019, then reached $377.9 million in 2021, then dropped by 9.65% to $341.5 million in 2022.